Johnson & Johnson’s (JNJ) “Overweight” Rating Reiterated at Cantor Fitzgerald

Johnson & Johnson (NYSE:JNJ)‘s stock had its “overweight” rating restated by research analysts at Cantor Fitzgerald in a research note issued on Monday, Benzinga reports. They currently have a $215.00 price objective on the stock. Cantor Fitzgerald’s target price would suggest a potential upside of 33.21% from the company’s current price.

Other analysts also recently issued reports about the stock. Daiwa Capital Markets downgraded shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $160.00 to $150.00 in a report on Tuesday, July 23rd. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a research note on Friday, September 20th. Morgan Stanley lifted their price target on Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a research note on Thursday, July 18th. Finally, TD Cowen decreased their price objective on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a report on Thursday, July 18th. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $173.21.

Johnson & Johnson Trading Up 0.0 %

JNJ opened at $161.40 on Monday. The firm’s fifty day moving average is $162.15 and its two-hundred day moving average is $154.16. The firm has a market cap of $388.44 billion, a PE ratio of 10.06, a price-to-earnings-growth ratio of 2.69 and a beta of 0.53. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, topping the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The firm had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. During the same period in the previous year, the company posted $2.80 earnings per share. The company’s revenue for the quarter was up 4.3% on a year-over-year basis. Equities research analysts anticipate that Johnson & Johnson will post 10.02 EPS for the current year.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Institutional Trading of Johnson & Johnson

Institutional investors have recently modified their holdings of the stock. Eagle Asset Management Inc. acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $1,446,000. CIBC Private Wealth Group LLC increased its stake in shares of Johnson & Johnson by 0.6% in the 4th quarter. CIBC Private Wealth Group LLC now owns 717,254 shares of the company’s stock valued at $112,422,000 after purchasing an additional 3,938 shares during the last quarter. Royal London Asset Management Ltd. raised its holdings in shares of Johnson & Johnson by 3.4% during the 4th quarter. Royal London Asset Management Ltd. now owns 1,619,599 shares of the company’s stock worth $253,856,000 after buying an additional 53,116 shares in the last quarter. ROI Financial Advisors LLC acquired a new stake in Johnson & Johnson in the fourth quarter valued at about $447,000. Finally, Edge Capital Group LLC grew its position in Johnson & Johnson by 12.0% in the fourth quarter. Edge Capital Group LLC now owns 111,673 shares of the company’s stock valued at $17,504,000 after acquiring an additional 12,000 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.